Cerevel Therapeutics Holdings, Inc. (CERE)
NASDAQ (CM) NASDAQ (CM) Primary 
Calling All Cerevel Therapeutics Holdings, Inc. (CERE) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your Losses
NEW YORK, NY / ACCESSWIRE / June 12, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Cerevel Therapeutics Holdings, Inc. ("Cerevel") (NASDAQ:CERE) and AbbVie, Inc. ("AbbVie") (NYSE:ABBV). Investors who purchased Cerevel and continue to holdto the present are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/cere.
CEREVEL STOCK NEWS: BFA Law Investigates Cerevel (Nasdaq:CERE) Following $45 Per Share Acquisition Offer, Investors are Reminded to Contact the Firm
NEW YORK, NY / ACCESSWIRE / June 11, 2024 / Leading law firm Bleichmar Fonti & Auld LLP is investigating the merger between Cerevel Therapeutics Holdings, Inc. (Nasdaq:CERE) and AbbVie, Inc. If you invested in Cerevel Therapeutics you are encouraged to obtain additional information by visiting Click Here . Claim Details: On December 6, 2023, Cerevel Therapeutics announced that it would be acquired by AbbVie.
Calling All Cerevel Therapeutics Holdings, Inc. (CERE) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your Losses
NEW YORK, NY / ACCESSWIRE / June 11, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Cerevel Therapeutics Holdings, Inc. ("Cerevel") (NASDAQ:CERE) and AbbVie, Inc. ("AbbVie") (NYSE:ABBV). Investors who purchased Cerevel and continue to holdto the present are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/cere.
Calling All Cerevel Therapeutics Holdings, Inc. (CERE) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your Losses
NEW YORK, NY / ACCESSWIRE / June 10, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Cerevel Therapeutics Holdings, Inc. ("Cerevel") (NASDAQ:CERE) and AbbVie, Inc. ("AbbVie") (NYSE:ABBV). Investors who purchased Cerevel and continue to holdto the present are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/cere.
After Plunging -5.14% in 4 Weeks, Here's Why the Trend Might Reverse for Cerevel Therapeutics (CERE)
Cerevel Therapeutics (CERE) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
CEREVEL INVESTIGATION NOTICE: Cerevel (CERE) Shareholders are Encouraged to Contact BFA Law About Their Rights in the $45 Merger Offer from AbbVie
NEW YORK, NY / ACCESSWIRE / June 10, 2024 / Leading law firm Bleichmar Fonti & Auld LLP is investigating the merger between Cerevel Therapeutics Holdings, Inc. (Nasdaq:CERE) and AbbVie, Inc. If you invested in Cerevel Therapeutics you are encouraged to obtain additional information by visiting Click Here Claim Details: On December 6, 2023, Cerevel Therapeutics announced that it would be acquired by AbbVie.
Calling All Cerevel Therapeutics Holdings, Inc. (CERE) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your Losses
NEW YORK, NY / ACCESSWIRE / June 9, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Cerevel Therapeutics Holdings, Inc. ("Cerevel") (NASDAQ:CERE) and AbbVie, Inc. ("AbbVie") (NYSE:ABBV). Investors who purchased Cerevel and continue to holdto the present are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/cere.
Calling All Cerevel Therapeutics Holdings, Inc. (CERE) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your Losses
NEW YORK, NY / ACCESSWIRE / June 7, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Cerevel Therapeutics Holdings, Inc. ("Cerevel") (NASDAQ:CERE) and AbbVie, Inc. ("AbbVie") (NYSE:ABBV). Investors who purchased Cerevel and continue to holdto the present are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/cere.
CEREVEL NEWS ALERT: BFA Law Announces Investigation of Cerevel (Nasdaq:CERE) Over the $45 Merger Offer, Investors are Encouraged to Contact the Firm
NEW YORK, NY / ACCESSWIRE / June 7, 2024 / Leading law firm Bleichmar Fonti & Auld LLP is investigating the merger between Cerevel Therapeutics Holdings, Inc. (Nasdaq:CERE) and AbbVie, Inc. If you invested in Cerevel Therapeutics you are encouraged to obtain additional information by visiting Click Here . Claim Details: On December 6, 2023, Cerevel Therapeutics announced that it would be acquired by AbbVie.
Calling All Cerevel Therapeutics Holdings, Inc. (CERE) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your Losses
NEW YORK, NY / ACCESSWIRE / June 6, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Cerevel Therapeutics Holdings, Inc. ("Cerevel") (NASDAQ:CERE) and AbbVie, Inc. ("AbbVie") (NYSE:ABBV). Investors who purchased Cerevel and continue to holdto the present are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/cere.
CEREVEL INVESTIGATION UPDATE: Cerevel (Nasdaq: CERE) Shareholders are Urged to Contact BFA Law about the $45 Merger Offer from AbbVie
NEW YORK, NY / ACCESSWIRE / June 6, 2024 / Leading law firm Bleichmar Fonti & Auld LLP is investigating the merger between Cerevel Therapeutics Holdings, Inc. (Nasdaq:CERE) and AbbVie, Inc. If you invested in Cerevel Therapeutics you are encouraged to obtain additional information by visiting Click Here . Claim Details: On December 6, 2023, Cerevel Therapeutics announced that it would be acquired by AbbVie.
Calling All Cerevel Therapeutics Holdings, Inc. (CERE) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your Losses
NEW YORK, NY / ACCESSWIRE / June 5, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Cerevel Therapeutics Holdings, Inc. ("Cerevel") (NASDAQ:CERE) and AbbVie, Inc. ("AbbVie") (NYSE:ABBV). Investors who purchased Cerevel and continue to holdto the present are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/cere.
